Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

NCT05513014 · clinicaltrials.gov ↗

COMPLETED

Status

1518

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals